Synthesis and
<i>in Vivo</i>
Evaluation of Triphenylphosphonium Conjugated Trimetazidine with Enhanced Cardioprotection and Ability to Restore Mitochondrial Function
作者:E Ou、Chao Xu、Qi Jia、Xiaojia Xu、Zhenyu Chen、Jiansong Liu、Hanyuan Zhang、Geng Xu、Yu Zhao
DOI:10.1002/cbdv.202200445
日期:2022.8
mitochondria. Fifteen triphenylphosphonium (TPP) conjugated trimetazidine analogs were designed and synthesized. Their protective effects were evaluated in vivo using a tert-butyl hydroperoxide (t-BHP) induced zebrafish injury model. Structure-activity relationship correlations revealed the best way to couple the TPP moiety to trimetazidine, and led to a new conjugate (18a) with enhanced therapeutic properties
曲美他嗪在心血管疾病中表现出巨大的治疗潜力,并且曲美他嗪对线粒体介导的心脏保护作用已被广泛报道。在这项研究中,为了增强其心脏保护作用,对曲美他嗪进行了基于三苯基鏻的修饰,以将其特异性递送至线粒体。设计并合成了十五种三苯基鏻 (TPP) 共轭曲美他嗪类似物。使用叔丁基过氧化氢 ( t - BHP) 诱导的斑马鱼损伤模型在体内评估了它们的保护作用。构效关系相关性揭示了将 TPP 部分与曲美他嗪偶联的最佳方法,并产生了一种新的偶联物(18a) 具有增强的治疗特性。与曲美他嗪相比,18a在低得多的浓度下可有效防止斑马鱼模型中的心脏损伤。对t -BHP 处理的斑马鱼和 H9c2 细胞的进一步研究表明,18a通过抑制 ROS 的过度产生、维持线粒体形态和防止线粒体功能障碍来防止心肌细胞死亡和损伤。因此,18a可被视为心脏保护的潜在治疗剂。